Literature DB >> 23252899

Functional defect in regulatory T cells in myasthenia gravis.

Muthusamy Thiruppathi1, Julie Rowin, Qin Li Jiang, Jian Rong Sheng, Bellur S Prabhakar, Matthew N Meriggioli.   

Abstract

Forkhead box P3 (FOXP3) is a transcription factor necessary for the function of regulatory T cells (T(reg) cells). T(reg) cells maintain immune homeostasis and self-tolerance and play an important role in the prevention of autoimmune disease. Here, we discuss the role of T(reg) cells in the pathogenesis of myasthenia gravis (MG) and review evidence indicating that a significant defect in T(reg) cell in vitro suppressive function exists in MG patients, without an alteration in circulating frequency. This functional defect is associated with a reduced expression of key functional molecules, such as FOXP3 on isolated T(reg) cells, and appears to be more pronounced in immunosuppression-naive MG patients. In vitro administration of granulocyte macrophage-colony-stimulating factor (GM-CSF) enhanced the suppressive function of T(reg) cells and upregulated FOXP3 expression. These findings indicate a clinically relevant T(reg) cell-intrinsic defect in immune regulation in MG that may reveal a novel therapeutic target.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23252899      PMCID: PMC3531815          DOI: 10.1111/j.1749-6632.2012.06840.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  58 in total

1.  Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy.

Authors:  Nicolette Moes; Frédéric Rieux-Laucat; Bernadette Begue; Julien Verdier; Bénédicte Neven; Natacha Patey; Troy T Torgerson; Capucine Picard; Marie-Claude Stolzenberg; Corinne Ruemmele; Edmond Hhm Rings; Jean-Laurent Casanova; Hugues Piloquet; Armand Biver; Anne Breton; Hans D Ochs; Olivier Hermine; Alain Fischer; Olivier Goulet; Nadine Cerf-Bensussan; Frank M Ruemmele
Journal:  Gastroenterology       Date:  2010-06-09       Impact factor: 22.682

2.  Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients.

Authors:  Masayuki Masuda; Moe Matsumoto; Sachiko Tanaka; Kanako Nakajima; Nao Yamada; Nobuhiro Ido; Takao Ohtsuka; Masashi Nishida; Toshihiko Hirano; Hiroya Utsumi
Journal:  J Neuroimmunol       Date:  2010-05-15       Impact factor: 3.478

3.  Single-cell analysis of the human T regulatory population uncovers functional heterogeneity and instability within FOXP3+ cells.

Authors:  Eva d'Hennezel; Ekaterina Yurchenko; Evridiki Sgouroudis; Valérie Hay; Ciriaco A Piccirillo
Journal:  J Immunol       Date:  2011-05-16       Impact factor: 5.422

4.  A candidate gene for autoimmune myasthenia gravis.

Authors:  Guida Landouré; Melanie A Knight; Horia Stanescu; Addis A Taye; Yijun Shi; Oumarou Diallo; Janel O Johnson; Dena Hernandez; Bryan J Traynor; Leslie G Biesecker; Abdel Elkahloun; Carlo Rinaldi; Angela Vincent; Nick Willcox; Robert Kleta; Kenneth H Fischbeck; Barrington G Burnett
Journal:  Neurology       Date:  2012-06-27       Impact factor: 9.910

5.  Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants.

Authors:  Wen-Hua Xu; Ai-Mei Zhang; Ming-Shan Ren; Xu-Dong Zhang; Fang Wang; Xiu-Cai Xu; Qing Li; Jian Wang; Bang-Sheng Din; Yuan-Bo Wu; Gui-Hai Chen
Journal:  J Clin Immunol       Date:  2012-03-31       Impact factor: 8.317

6.  GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis.

Authors:  Jian Rong Sheng; Thiruppathi Muthusamy; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  J Neuroimmunol       Date:  2011-11-17       Impact factor: 3.478

7.  Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells.

Authors:  Julie Rowin; Muthusamy Thiruppathi; Ebinehita Arhebamen; Jianrong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Muscle Nerve       Date:  2012-09       Impact factor: 3.217

8.  Identification of IL-17-producing FOXP3+ regulatory T cells in humans.

Authors:  Kui Shin Voo; Yui-Hsi Wang; Fabio R Santori; Cesar Boggiano; Yi-Hong Wang; Kazuhiko Arima; Laura Bover; Shino Hanabuchi; Jahan Khalili; Ekaterina Marinova; Biao Zheng; Dan R Littman; Yong-Jun Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-09       Impact factor: 11.205

9.  Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Balaji Ganesh; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Clin Immunol       Date:  2012-10-07       Impact factor: 3.969

10.  Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population.

Authors:  Angelina H Maniaol; Ahmed Elsais; Åslaug R Lorentzen; Jone F Owe; Marte K Viken; Hanne Sæther; Siri T Flåm; Geir Bråthen; Margitta T Kampman; Rune Midgard; Marte Christensen; Anna Rognerud; Emilia Kerty; Nils Erik Gilhus; Chantal M E Tallaksen; Benedicte A Lie; Hanne F Harbo
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

View more
  24 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis.

Authors:  Valentina Catzola; Alessandra Battaglia; Alexia Buzzonetti; Marco Fossati; Flavia Scuderi; Andrea Fattorossi; Amelia Evoli
Journal:  J Neurol       Date:  2013-06-08       Impact factor: 4.849

Review 3.  Regulatory T cells in autoimmune disease.

Authors:  Margarita Dominguez-Villar; David A Hafler
Journal:  Nat Immunol       Date:  2018-06-20       Impact factor: 25.606

Review 4.  Myasthenia gravis: an update for the clinician.

Authors:  J P Sieb
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 5.  Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy.

Authors:  Palash Bhattacharya; Isadore Budnick; Medha Singh; Muthusamy Thiruppathi; Khaled Alharshawi; Hatem Elshabrawy; Mark J Holterman; Bellur S Prabhakar
Journal:  J Interferon Cytokine Res       Date:  2015-03-24       Impact factor: 2.607

6.  Highly heterogeneous, activated, and short-lived regulatory T cells during chronic filarial infection.

Authors:  Simon Metenou; Yaya I Coulibaly; Daniel Sturdevant; Housseini Dolo; Abdallah A Diallo; Lamine Soumaoro; Michel E Coulibaly; Kishore Kanakabandi; Stephen F Porcella; Amy D Klion; Thomas B Nutman
Journal:  Eur J Immunol       Date:  2014-05-22       Impact factor: 5.532

7.  The effect of interleukin (IL)-21 and CD4+ CD25++ T cells on cytokine production of CD4+ responder T cells in patients with myasthenia gravis.

Authors:  M Alahgholi-Hajibehzad; H Durmuş; F Aysal; Y Gülşen-Parman; P Oflazer; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2017-07-28       Impact factor: 4.330

Review 8.  Genetic engineering of T cells for immunotherapy.

Authors:  Gavin I Ellis; Neil C Sheppard; James L Riley
Journal:  Nat Rev Genet       Date:  2021-02-18       Impact factor: 59.581

9.  Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes.

Authors:  ZhaoHui Luo; Ye Li; XiaoFang Liu; MengChuan Luo; LiQun Xu; YueBei Luo; Bo Xiao; Huan Yang
Journal:  BMC Med Genomics       Date:  2015-03-18       Impact factor: 3.063

Review 10.  Recent advances in genetic predisposition of myasthenia gravis.

Authors:  Zoi Zagoriti; Manousos E Kambouris; George P Patrinos; Socrates J Tzartos; Konstantinos Poulas
Journal:  Biomed Res Int       Date:  2013-11-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.